-
WuXi Biologics and Hequan Pharmaceuticals establish a joint venture company WuXi Helian focuses on integrated biologic conjugates CDMO
Time of Update: 2021-07-06
With the establishment of WuXi Helian, we will better integrate the industry-leading resources of Hequan Pharmaceutical and WuXi Biologics in their respective fields, and further optimize the platform capabilities of bio-conjugated drug R&D and production , To support more new drugs on the market faster and benefit more patients .
-
Johnson & Johnson's ACUVUE Abiliti night-wearing contact lens obtained FDA approval
Time of Update: 2021-07-06
The FDA approval of Abiliti™ night-wearing contact lenses will provide eye health professionals and parents with more options for managing myopia .
Under the new brand of Abiliti™, the company will launch a series of products and services to help parents and eye health professionals cope with the development of children's myopia .
-
Tianjing Bio is included in the MSCI China Index
Time of Update: 2021-07-06
The MSCI China Index is recognized as an important indicator for global professional investors to invest in the Chinese market and optimize their investment portfolio .
As one of the few Chinese biotech companies selected by MSCI, Tianjing Biological is currently stepping into a comprehensive global biopharmaceutical company in an orderly manner .
-
BeiGene announced that the FDA has accepted the application for new indications of BeiGene for marginal zone lymphoma
Time of Update: 2021-07-06
S. Food and Drug Administration (FDA) has accepted Baiyueze® (Zebutinib) for the treatment of adult marginal zone lymphoma (MZL) patients who have previously received at least one CD20-directed therapy.
-
The National Medical Products Administration accepts the application for the marketing authorization of the biologics of Genting Xinyao's innovative drug Gosartuzumab for the treatment of metastatic triple-negative breast cancer
Time of Update: 2021-07-06
Everest Medicines (HKEX 1952. HK), a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to meeting the unmet medical needs of Greater China
-
OptraSCAN announces the launch of CytoSiA
Time of Update: 2021-07-06
OptraSCAN®, the world's leading provider of on-demand digital pathology solutions, today announced the launch of its smart solution CytoSiA, which can quickly and economically scan and analyze liquid-based cytology sections and Pap smears .
-
Roche Aimanxin® is approved in China!
Time of Update: 2021-07-06
On June 16, 2021, the National Medical Products Administration of China officially approved Roche's heavy neurological innovation drug Lisporan oral solution powder (Chinese product name: Aimanxin®, English product name: Evrysdi®) for use in Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older .
-
Innovent announces that Pemigatinib for the first-line treatment of unresectable or metastatic cholangiocarcinoma's global phase 3 registered clinical trial has completed the first patient dosing in China
Time of Update: 2021-07-06
Cinda Biopharmaceuticals, a biopharmaceutical company dedicated to the development, production and sales of innovative drugs for the treatment of tumors, autoimmune, metabolic diseases and other major diseases, today announced: pemigatinib (R&D code IBI375, FGFR1/2/3 inhibitor ) Phase 3 registration clinical study has completed the enrollment and administration of the first patient with unresectable or metastatic cholangiocarcinoma in China .
-
Refuge, a shareholding company of 3SBio, cooperates with MD Anderson Cancer Center
Time of Update: 2021-07-06
, a shareholding company of 3SBio, and the University of Texas MD Anderson Cancer Center announced a strategic cooperation to develop new smart cells for the treatment of solid tumors .
-
Concerned about the health of the new "intestinal" disease popular science activity held in Shanghai
Time of Update: 2021-07-06
At the event site, dietitians were also invited to explain the knowledge of diet, nutrition and health for patients and audiences, and through creative culinary challenges, to customize healthy and nutritious meals for IBD patients to help patients achieve "freedom of food" and improve their quality of life .
-
China Resources Double Crane: Parecoxib Sodium API passed CDE technical review
Time of Update: 2021-07-06
At present, there are 36 companies that have registered parecoxib sodium on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information disclosure platform, of which 24 companies have been approved as "A" in the joint review and approval of the preparations .
-
BD Medical brings upstream and downstream partners to attend China International Medical Equipment Expo 2021
Time of Update: 2021-07-06
In recent years, it has established a localized service From R&D to production to supply chain management, we are the beneficiaries of this process, and we are also willing to continue to further explore local innovation in the future, and work with external partners to empower upstream and downstream industries to jointly build China's medical industry.
-
Ipsen lays out in the big health field and joins hands with Neptune Star to increase national health
Time of Update: 2021-07-06
In April this year, the Kangmax series of health care products officially entered the Neptune Star chain pharmacy, continuing to create new consumer awareness of family nutrition and health .
-
Siemens Medical Develops Emergency and Critical Care Solutions in Laboratory
Time of Update: 2021-07-06
Siemens Medical, the world's leading medical technology company, unveiled its new Atellica emergency and critical care solution, helping the emergency laboratory department to simultaneously improve the speed and accuracy of reporting, saving patients' lives in a timely manner, improving operational efficiency, optimizing work processes, and greatly reducing Hospital emergency department pressure .
-
Shanghai Pharmaceuticals plans to raise funds not to exceed 14.384 billion
Time of Update: 2021-07-06
On May 11, Shanghai Pharmaceuticals issued a plan for non-public issuance of A shares .
According to the plan, Shanghai Pharmaceuticals intends to issue a total of no more than 852,626,796 A shares to Yunnan Baiyao Group Co.
-
Hutchison Whampoa Sofantinib's new indication will be approved soon
Time of Update: 2021-07-06
According to Hutchison Whampoa’s announcement, the indication is advanced pancreatic neuroendocrine tumor .
On December 30 last year, Sofantinib was just approved for marketing for late-stage well-differentiated neuroendocrine tumors of non-pancreatic origin .
-
The results of the first-line clinical study of Hausen Pharmaceuticals Amelia will be announced at ASCO
Time of Update: 2021-07-06
independently developed a category 1 innovative drug Amelo® (Ametinib mesylate) for the first-line treatment of EGFR The data of the Phase III clinical study of sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) will be announced at the 2021 ASCO annual meeting .
-
"Magic bullet" ADC drug 10 billion gold track competition intensifies!
Time of Update: 2021-07-06
Recently, the domestic news about ADC drug research and development dynamics refreshed the screen On May 18, the innovative ADC introduced by Xinma Biology is planned to be included in the breakthrough treatment product; On May 17, Genting Xinyao Trodelvy (Gosartuzumab for injection)’s biological product marketing authorization application was accepted by the State Food and Drug Administration.
-
CSPC's anti-Claudin 18.2 ADC was approved for clinical use
Time of Update: 2021-07-06
On June 16, CSPC issued an announcement that the Antibody-Drug Conjugate SYSA1801 developed by the Group has been approved by the National Medical Products Administration for clinical research in China .
This product is the second clinically approved ADC targeting Claudin 18.
-
Controversy between monoclonal antibodies and double antibodies-can double antibodies replace monoclonal antibodies?
Time of Update: 2021-07-06
In February of this year, Amgen announced the temporary suspension of clinical studies of three dual-antibody drugs, including AMG596 (EGFR×CD3), AMG701 (BCMA×CD3), AMG673 (CD33×CD3), among which, BCMA×CD3 is the target The reason for the suspension of AMG-701 may be CRS (Cytokine Release Syndrome) or peripheral nerve damage .
